Clinical Trials Logo

Filter by:
NCT ID: NCT02112305 Active, not recruiting - Acute Severe Asthma Clinical Trials

Compare Efficacy Nebulized and Intravenous Magnesium Sulphate in Thai Children

Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether nebulized magnesium sulphate is effective in the treatment of acute severe asthma when comparison with intravenous magnesium sulphate

NCT ID: NCT02103764 Active, not recruiting - Clinical trials for Dysfunctional Uterine Bleeding

Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB

SI-AUB-RCT
Start date: August 2013
Phase: Phase 3
Study type: Interventional

The objectives of the present study is to determine the effectiveness of cyclic desogestrel (DSG) compared with cyclic medroxyprogesterone acetate for the treatment of anovulatory dysfunctional uterine bleeding (DUB) in the following aspects: 1. Endometrial histopathology changes 2. Menstrual cycle control.

NCT ID: NCT02087423 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

ATLANTIC
Start date: February 25, 2014
Phase: Phase 2
Study type: Interventional

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability

NCT ID: NCT02075840 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

ALEX
Start date: August 19, 2014
Phase: Phase 3
Study type: Interventional

This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma kinase-positive (ALK-positive) advanced non-small cell lung cancer (NSCLC). Participants will be randomized in a 1:1 ratio to receive either alectinib, 600 milligrams (mg) orally twice daily (BID), or crizotinib, 250 mg orally BID. Participants will receive treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death. The study is expected to last approximately 144 months.

NCT ID: NCT02003924 Active, not recruiting - Prostate Cancer Clinical Trials

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

PROSPER
Start date: October 31, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

NCT ID: NCT01981967 Active, not recruiting - Clinical trials for Japanese Encephalitis

Post-licensure Safety Study of IMOJEV® in Thailand

Start date: November 2013
Phase: Phase 4
Study type: Interventional

The aim of this study is to further characterize the safety profile of IMOJEV®. Primary Objective: - To describe serious adverse events (SAEs, including adverse events of special interest [AESIs]) up to 60 days after administration of one dose of IMOJEV®. Secondary Objective: - To describe Grade 3 (severe) systemic Adverse Events (AEs) up to 30 minutes after administration of one dose of IMOJEV®.

NCT ID: NCT01942421 Active, not recruiting - Clinical trials for Ocular Surface Disease

Ocular Surface Reconstruction With Cultivated Autologus Mucosal Epithelial Transplantation

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to elucidate the appropriate condition of developing cultivated autologous oral mucosal epithelial graft and evaluate the surgical outcome of transplantation of the cultivated cells in the patients.

NCT ID: NCT01933685 Active, not recruiting - HIV Infections Clinical Trials

Study of Immune Responses Induced by a HIV Vaccine

Start date: July 3, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to define the immune responses induced by a HIV vaccine, AIDSVAX B/E. Blood and mucosal samples will be collected to assess immune responses.

NCT ID: NCT01931358 Active, not recruiting - HIV Infections Clinical Trials

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E

Start date: September 24, 2013
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to better define the relative contributions of AIDSVAX® B/E alone, ALVAC-HIV alone, or ALVAC-HIV plus AIDSVAX® B/E combination to the observed immune profile in the weeks and months after receiving the original prime and boost vaccine regimen from study protocol RV 144, and their booster effects in both the systemic and mucosal compartments. In addition, this study will provide more intensive and comprehensive characterization of the innate, cell-mediated and humoral immune responses than possible within the RV 144 study.

NCT ID: NCT01856478 Active, not recruiting - Clinical trials for Head and Neck Neoplasms

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Start date: May 23, 2013
Phase: Phase 3
Study type: Interventional

This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.